ClinicalTrials.gg
Not yet recruitingNCT07499115Updated Apr 13, 2026

Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding

A Phase 3 interventional study of Toothpaste containing chitosan and Colgate Cavity Protection Toothpaste in Plaque, Dental and Gingivitis, sponsored by Colgate Palmolive. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To assess the efficacy of a toothpaste containing chitosan in reducing plaque, gingivitis, and gingival bleeding, compared with Colgate Cavity Protection Toothpaste

02

Conditions studied

  • Plaque, Dental
  • Gingivitis
03

In context

Dental Plaque

352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

This study's planned enrollment of 90 is above the median of 56 across 316 interventional studies indexed under Dental Plaque.

Browse Dental Plaque studies →

Lead sponsor

Colgate Palmolive is the lead sponsor of 119 studies on the registry; 13 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-70 years (inclusive).
  • Available for the duration of the study.
  • Able to understand and willing to read and sign the Form after the nature of the study has been fully explained.
  • Willing to comply with all study procedures and clinical examination schedules.
  • Good general health (absence of any condition that, in the opinion of the study examiner, might pose risk during participation; e.g., certain heart conditions, valve/hip replacements).
  • Presence of at least 20 natural teeth (excluding third molars) with scorable facial and lingual surfaces.
  • Mean Modified Gingival Index (MGI, Lobene) ≥ 2.0 and Mean Modified Plaque Index (MPI, Turesky) ≥ 1.5 at screening.
  • Willing and able to complete study questionnaires on product usage experience during routine toothbrushing.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating.
  • Use of tobacco products.
  • History of alcohol or drug abuse.
  • Any medical condition (e.g., significant heart or liver disease, bleeding disorders, blood dyscrasias) or current medication use that, in the investigator's judgment, may compromise subject safety or the quality of study results.
  • Medical condition requiring pre-medication prior to dental visits/procedures.
  • History of allergy to oral hygiene products.
  • Use of anti-inflammatory, , antimicrobial, or anticoagulant drugs, or antibiotics within 30 days prior to study start or during the study.
  • Ongoing use of medications known to affect gingival tissues (e.g., calcium channel blockers, phenytoin, cyclosporine).
  • Presence of orthodontic bands or removable partial dentures.
  • Tumors of the soft or hard tissues of the oral cavity.
  • Five or more carious lesions requiring immediate restorative treatment.
  • More than two periodontal pockets (>4 mm) with bleeding on probing.
  • Any gingival condition (e.g., hyperplasia or overgrowth) that would interfere with clinical assessment.
  • Participation in another clinical study with an oral care indication or test panel within 30 days prior to study start.
  • Medical condition that prohibits abstaining from eating or drinking for up to 2 hours.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Test Toothpaste

    Daily toothbrushing, Twice daily, 2 minutes each time

    Drug: Toothpaste containing chitosan

  • Active comparator
    Control Toothpaste

    Daily toothbrushing, Twice daily, 2 minutes each time

    Drug: Colgate Cavity Protection Toothpaste

Interventions

  • DrugToothpaste containing chitosan

    Toothpaste containing chitosan and a commercially available soft-bristled toothbrush

  • Fluoride Toothpaste and a commercially available soft-bristled toothbrush

06

What researchers measure

Primary outcomes

  1. Modified Gingival Index (MGI_ Lobene)

    Clinical assessments will be carried out using the Modified Gingival Index (MGI; Lobene et al., 1986).MGI scoring criteria: 0: Absence of inflammation 1. Mild inflammation; slight change in color, little change in texture of any portion of, but not the entire, marginal or papillary gingival unit 2. Mild inflammation; as above, but involving the entire marginal or papillary gingival unit 3. Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4. Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: Baseline, 2 week, 1 month & 3 month

  2. Modified Plaque Index (MPI_ Turesky)

    Using a red disclosing solution, a Modified Plaque Index (Turesky et al, 1970) score of 0-5 will be assigned to all scorable disclosed surfaces of the maxillary and mandibular teeth using a dental light and dental mirror. A whole-mouth score will be determined by summing the values for all scorable surfaces and dividing by the total number of surfaces scored. Modified Plaque Index (Turesky) scoring criteria: 0: No plaque 1. Separate flecks of plaque at the cervical margin 2. A thin, continuous band of plaque (up to 1 mm) at the cervical margin 3. A band of plaque wider than 1 mm but covering less than one-third of the crown 4. Plaque covering at least one-third but less than two-thirds of the crown 5. Plaque covering two-thirds or more of the crown

    Time frame: Baseline, 2 week, 1 month & 3 month

  3. Gingival Bleeding Index (GBI_ Saxton)

    The examiner will conduct the Gingival Bleeding Index (GBI) examinations using the Saxton and van der Ouderaa methodology and a CPITN periodontal probe (0.5 mm ball end). Findings and GBI score calculations (including bleeding severity) will be recorded on the Gingival Bleeding Index Examination Form.

    Time frame: Baseline, 2 week, 1 month & 3 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.

Of 20 phase 3 interventional studies under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's planned 3 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Apr 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07499115
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Apr 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Deyu Hu, DDS
Contact
hudeyu@vip.sina.com
1390-803-4990
Deyu Hu
principal investigator · West China Dental Institute of Chengdu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion